Key result
NSAIDs and COX-2 inhibitors are effective for pain but carry substantial risks of gastrointestinal toxicity and adverse cardiovascular events, requiring individualized therapy selection.
Why the study?
What are the gastrointestinal and cardiovascular risks associated with NSAIDs and COX-2 inhibitors?
What are the gastrointestinal and cardiovascular risks associated with NSAIDs and COX-2 inhibitors?
Answers are grounded in this paper and cite their sources.
The selection of an appropriate analgesic or anti-inflammatory agent should be individualized based on gastrointestinal and cardiovascular risk profiles.
Nonsteroidal anti-inflammatory drugs (NSAIDs) confer a gastrointestinal (GI) side effect profile and concerns regarding adverse cardiovascular effects have emerged associated with considerable morbidity and mortality. NSAIDs are highly effective in treating pain and inflammation, but it is well recognized that these agents are associated with substantial gastrointestinal toxicity. Cyclo-oxygenase-2 inhibitors may also reduce the risk for gastrointestinal events, although they may increase cardiovascular adverse events. The selection of an appropriate analgesic or anti-inflammatory agent with or without gastroprotective therapy should be individualized.
No takes yet. Share an insight, caveat, or question.
Abdulwahed Al-Saeed (2011) conducted a review in Pain and inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) and Cyclo-oxygenase-2 inhibitors was evaluated. NSAIDs and COX-2 inhibitors are effective for pain but carry substantial risks of gastrointestinal toxicity and adverse cardiovascular events, requiring individualized therapy selection.
Synapse has enriched 10 related papers. Consider them for comparative context: